Seattle Genetics Acquires Cascadian Therapeutics, Continuing a Strong ...


On January 31, two Seattle biotech companies, Seattle Genetics and Cascadian Therapeutics, announced a merger agreement under which Seattle Genetics will acquire Cascadian Therapeutics for $614 million. [1] The announcement catapulted Cascadian Therapeutics shares to a 16-month high, and a 69% increase over the previous day's closing price.



from Biotech News